Author: Christina Fasano

Benefit-cost analysis is well-established and widely used to inform policy decisions. Its normative foundations are explored in “Ethics and Benefit-Cost Analysis,” a special issue of the Journal of Benefit

CHDS’s Ole Norheim served as one of the editors to the fourth edition of the Disease Control Priorities (DCP-4) Country-Led Priorities Setting for Health volume, released last month. This is the first of four volumes

Conventional methods for valuing health and longevity have several well-known limitations. In a CHDS seminar, Maddalena Ferranna discussed social welfare function analysis

Jacob Jameson, third year doctoral student in Health Policy, and CHDS faculty Soroush Saghafian published a study examining how physician variation in batch versus sequential test ordering in the emergency

CHDS is delighted to welcome Ole F. Norheim as CHDS Affiliate Faculty. Norheim recently joined the Harvard Chan School faculty as Mary B. Saltonstall Professor of Ethics and Population Health

CHDS faculty Nicole Campos and a team of researchers at the National Cancer Institute (NCI), including Principal Deputy Director of the NCI Douglas Lowy, Senior Investigator Mark Schiffman, and

CHDS faculty Sue J. Goldie and Stéphane Verguet served on The Lancet  Commission on Investing in Health, which recently released Global Health 2050: The Path to Halving Premature Death by

Understanding who gains and who loses from policy interventions is essential to sound decision-making. However, assessing the distributional equity of policy impacts is very challenging.

CHDS’ Stéphane Verguet and colleagues recently published in Nature Medicine that reducing preventable deaths from major noncommunicable diseases (NCDs) and injuries around the world

In a recent study, CHDS’ Nicolas Menzies and colleagues used mathematical modelling to quantify the potential health impact and cost-savings for a hypothetical pan-tuberculosis regimen